-+ 0.00%
-+ 0.00%
-+ 0.00%

Aelis Farma’s AEF0217 Phase 2b Trial Gets Second Safety Panel Backing to Continue Unchanged

PUBT·11/15/2026 20:52:47
Listen to the news
Aelis Farma’s AEF0217 Phase 2b Trial Gets Second Safety Panel Backing to Continue Unchanged
  • Aelis Farma received a second independent safety endorsement to continue its Phase 2b AEF0217 trial in Down syndrome without protocol changes.
  • Safety findings released Nov. 16, 2026, showed favorable tolerability, with no serious or severe adverse events.
  • The monitoring committee also supported a potential 12-month open-label extension to collect longer-term safety data.
  • Clinical results remain expected by year-end 2027, aiming to confirm earlier findings of improved adaptive behavior and cognitive function.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aelis Farma SA published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.